ES2170720B1 - Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus. - Google Patents

Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.

Info

Publication number
ES2170720B1
ES2170720B1 ES200003056A ES200003056A ES2170720B1 ES 2170720 B1 ES2170720 B1 ES 2170720B1 ES 200003056 A ES200003056 A ES 200003056A ES 200003056 A ES200003056 A ES 200003056A ES 2170720 B1 ES2170720 B1 ES 2170720B1
Authority
ES
Spain
Prior art keywords
gene
development
insulin
therapeutic
glucoquinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200003056A
Other languages
English (en)
Other versions
ES2170720A1 (es
Inventor
Tubert Fatima Bosch
Goya Pedro Otaegui
Pastor Efren Riu
Masferrer Tura Ferri
Monteys Alejandro Mas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat Autonoma de Barcelona UAB
Original Assignee
Universitat Autonoma de Barcelona UAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat Autonoma de Barcelona UAB filed Critical Universitat Autonoma de Barcelona UAB
Priority to ES200003056A priority Critical patent/ES2170720B1/es
Priority to EP01271144A priority patent/EP1360898A1/en
Priority to CA002432506A priority patent/CA2432506A1/en
Priority to AU2002216125A priority patent/AU2002216125A1/en
Priority to US10/451,091 priority patent/US20040055023A1/en
Priority to PCT/ES2001/000493 priority patent/WO2002049423A1/es
Publication of ES2170720A1 publication Critical patent/ES2170720A1/es
Application granted granted Critical
Publication of ES2170720B1 publication Critical patent/ES2170720B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilización conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapéuticas para la diabetes mellitus. La presente invención se refiere a un animal doble transgénico que expresa simultáneamente el gen o el cDNA (ADN complementario) de la insulina y el gen o el cDNA (ADN complementario) de la glucoquinasa dirigidos por un promotor o fusión de promotores que permiten expresar insulina y glucoquinasa en músculo y su utilización en el desarrollo de aproximaciones terapéuticas para la diabetes mellitus. La presente invención también se refiere a un vector o vectores de expresión que permite expresar conjuntamente dichos genes quiméricos en células musculares. Dichos vectores pueden ser un plásmido, un vector viral o un vector no viral.
ES200003056A 2000-12-20 2000-12-20 Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus. Expired - Fee Related ES2170720B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES200003056A ES2170720B1 (es) 2000-12-20 2000-12-20 Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
EP01271144A EP1360898A1 (en) 2000-12-20 2001-12-19 Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
CA002432506A CA2432506A1 (en) 2000-12-20 2001-12-19 Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
AU2002216125A AU2002216125A1 (en) 2000-12-20 2001-12-19 Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
US10/451,091 US20040055023A1 (en) 2000-12-20 2001-12-19 Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
PCT/ES2001/000493 WO2002049423A1 (es) 2000-12-20 2001-12-19 Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200003056A ES2170720B1 (es) 2000-12-20 2000-12-20 Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.

Publications (2)

Publication Number Publication Date
ES2170720A1 ES2170720A1 (es) 2002-08-01
ES2170720B1 true ES2170720B1 (es) 2003-12-16

Family

ID=8496075

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200003056A Expired - Fee Related ES2170720B1 (es) 2000-12-20 2000-12-20 Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.

Country Status (6)

Country Link
US (1) US20040055023A1 (es)
EP (1) EP1360898A1 (es)
AU (1) AU2002216125A1 (es)
CA (1) CA2432506A1 (es)
ES (1) ES2170720B1 (es)
WO (1) WO2002049423A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
KR101300540B1 (ko) * 2009-01-07 2013-09-02 하이동 후앙 인간 글루코키나제 돌연변이체 코딩 유전자, 이에 의하여 코딩된 효소, 재조합 벡터 및 숙주, 이의 약학적 조성물 및 용도, 및 질병의 예방 및 치료 방법
US9309534B2 (en) 2010-07-12 2016-04-12 Universidad Autonoma De Barcelona Gene therapy composition for use in diabetes treatment
WO2013117776A1 (es) * 2012-02-08 2013-08-15 Fundación Pública Andaluza Progreso Y Salud Enzimas glucocinasas con actividad aumentada y su uso en el tratamiento y/o prevención de la diabetes mellitus
EP2692868A1 (en) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
CA2960912A1 (en) 2014-09-16 2016-03-24 Universitat Autonoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
EP3242945B1 (en) 2015-01-07 2021-09-01 Universitat Autònoma de Barcelona Single-vector gene construct comprising insulin and glucokinase genes
IL306098A (en) 2017-05-24 2023-11-01 Univ Barcelona Autonoma Viral expression vectors containing the coding sequence for FIBROBLAST GROWTH FACTOR 21 (FGF21)
CA3137622A1 (en) 2019-07-10 2021-01-14 Masonic Medical Research Institute Vgll4 with ucp-1 cis-regulatory element and method of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687836B2 (en) * 1993-06-28 1998-03-05 Board Of Regents, The University Of Texas System Vectors for genetically engineered cells that produce insulin in response to glucose
AU6258894A (en) * 1994-03-14 1995-10-03 Universitat Autonoma De Barcelona Chimeric gene using the gene or cdna of insuline, specially for the gene therapy of diabetes
ZA969435B (en) * 1995-11-16 1997-06-02 Antonomous University Of Barce Treatment of diabetes with a glucokinase gene
AU1557000A (en) * 1998-11-20 2000-06-13 Autonomous University of Barcelona, The Insulin production by engineered muscle cells

Also Published As

Publication number Publication date
EP1360898A1 (en) 2003-11-12
WO2002049423A1 (es) 2002-06-27
AU2002216125A1 (en) 2002-07-01
ES2170720A1 (es) 2002-08-01
CA2432506A1 (en) 2002-06-27
US20040055023A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
ES2170720B1 (es) Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
McManaman et al. Lipid droplet targeting domains of adipophilin
MX2025009543A (es) Variantes fc con union mejorada a fcrn y semivida prolongada
ES2847698T3 (es) Construcción de ácido nucleico
SG158158A1 (en) Glp-1 agonists, compositions, methods and uses
CR20220279A (es) Análogos de incretina y sus usos
ES2080341T3 (es) Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral.
AR062030A1 (es) Proteinas de fusion de exendina
NO20064953L (no) Human GLP-1 mimetilegemer, sammensetninger, fremgangsmater og anvendelser
WO2006096815A3 (en) NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
SG178940A1 (en) Products and methods for enhanced transgene expression and processing
WO2018231018A3 (ko) 간에서 목적하는 단백질 발현하기 위한 플랫폼
PH12023550145A1 (en) Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences
Benjamin et al. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung.
DE60328673D1 (de) Optimierung von transgenexpression in säugetierzellen
Xu et al. Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice
BR0209551A (pt) Promotor de gene especìfico de folha de café
US20180237491A1 (en) Optogenetic Inhibition of Overactive Neuronal Activity
DK1634955T3 (da) Konditionale genvektorer, der er reguleret i cis
ES2156788B1 (es) Genes quimericos que utilizan el cdna en orientacion antisentido del transportador de glucosa-2 (glut2) y animales transgenicos no humanos que expresan dichos genes quimericos para su utilizacion en el estudio de la diabetes mellitus y en el desarrollo de aproximaciones terapeuti
WO2004024867A3 (en) Vigilant vector system
ES2156460B1 (es) Animal transgenico no humano que sobreexpresa el gen de la p-enolpiruvato carboxiquinasa para su utilizacion en el estudio de la diabetes mellitus y en el desarrollo de aproximaciones terapeuticas a la enfermedad.
UA88601C2 (ru) Промотор il-18bp, его получение и применение
GB2450688A (en) Ovalbumin promoter constructs for retroviral vectors

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020801

Kind code of ref document: A1

Effective date: 20020801

FG2A Definitive protection

Ref document number: 2170720B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20210326